Roche Holding AG

The global disposable medical device sensors market is projected to grow from USD 11.86 billion in 2026 to USD 16.13 billion by 2031, a compound annual growth rate of 6.4%, according to a new ResearchAndMarkets.com report. Growth is driven by the rising prevalence of chronic and infectious diseases, remote patient monitoring, point-of-care diagnostics, wearable devices, home healthcare, and infection-prevention needs. By type, biosensors currently hold the largest share of the market, while strip sensors are expected to capture the largest share over the forecast period. The United States is expected to record the highest CAGR within North America, supported by advanced healthcare infrastructure and high adoption of innovative medical technologies. Key players profiled include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Medtronic, and GE HealthCare Technologies Inc.

Roche announced new data from the VOYAGER study confirming the real-world effectiveness, durability and safety of Vabysmo, also known as faricimab, in neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. The results, presented at the EURETINA 2026 Annual Meeting in Vienna, Austria, showed vision gains and anatomical improvements in previously untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes across all study cohorts. In the nAMD and DME cohorts, vision and central subfield thickness improved in previously untreated eyes after 12 months of treatment, while in the central and hemi-RVO cohort both vision and CST improved in untreated and treated eyes after six months. With more than 5,000 patients enrolled across 28 countries and regions, VOYAGER is the largest prospective, non-interventional real-world dataset evaluating Vabysmo, and the study's safety profile was generally consistent with that established in Phase III trials. Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the sustained visual improvements and meaningful anatomical drying reinforce the role of Vabysmo in addressing unmet needs for patients with retinal conditions. Vabysmo is approved in more than 100 countries for nAMD and DME and in more than 60 countries for macular edema following RVO.

Roche announced that detailed results from the phase III evERA Breast Cancer study, showing investigational giredestrant plus everolimus significantly improved progression-free survival versus standard endocrine therapy plus everolimus, were published in The New England Journal of Medicine. In the ESR1-mutated population, median PFS was 10.0 months with the giredestrant combination compared with 5.5 months in the comparator arm, a stratified hazard ratio of 0.38, while in the intent-to-treat population median PFS was 8.8 months versus 5.5 months, a hazard ratio of 0.56, corresponding to a 44% reduction in the risk of disease progression or death in the ITT population and 62% in the ESR1-mutated population. Overall survival data were immature but showed a clear positive trend in both the ITT population, with a hazard ratio of 0.69, and the ESR1-mutated population, with a hazard ratio of 0.62, and adverse events were manageable with no unexpected safety findings, including no photopsia and low rates of bradycardia. Based on these data, the US Food and Drug Administration accepted Roche's New Drug Application for giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, with a decision expected by 18 December 2026, and also accepted a Priority Review NDA for giredestrant as adjuvant treatment in early breast cancer based on the lidERA results, with a Prescription Drug User Fee Act goal date of 30 November 2026. evERA was the first positive phase III readout for giredestrant, followed by the lidERA Breast Cancer study in the early-stage setting, and additional analyses presented at the 2026 American Society of Clinical Oncology Annual Meeting showed the combination prolongs PFS2 and chemotherapy-free survival compared with standard endocrine therapy.

TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease, and provides private and academic hospital laboratories with a ready-to-use solution that integrates into existing workflows on established LightCycler systems. Marcus Droege, CEO of TIB MOLBIOL, said catching these diseases before symptoms appear is the difference between a child thriving or facing severe, lifelong disability, and that expanding the company's compliant newborn screening tools across Europe helps laboratories transition to high-precision solutions. Early diagnosis of SMA allows clinicians to immediately initiate targeted therapies that may halt severe nerve damage and prevent permanent disability, while early detection of SCD enables preventive penicillin and specialised immunisations that can drastically lower infant mortality, and early detection of SCID allows for lifesaving treatments such as bone marrow transplants before dangerous infections occur.

Roche announced that the United States Food and Drug Administration has accepted its New Drug Application under priority review for fenebrutinib, an investigational non-covalent BTK inhibitor for relapsing multiple sclerosis and primary progressive multiple sclerosis, making it the first BTK inhibitor to receive FDA filing acceptance in both forms of the disease. The filing is backed by three Phase III studies: in the FENhance 1 and 2 relapsing MS trials, fenebrutinib cut the annualised relapse rate by 51.1% and 58.5% versus teriflunomide over 96 weeks, while in the FENtrepid primary progressive MS study it met its primary endpoint of non-inferiority against Ocrevus and numerically reduced the risk of disability progression by 12%, with a hazard ratio of 0.88. Roche Chief Medical Officer Levi Garraway said the three Phase III studies demonstrated the potential for fenebrutinib to address both relapsing and progressive disease, and Pharma CEO Teresa Graham said the drug could become the first high-efficacy oral therapy for both relapsing and primary progressive MS. If approved, fenebrutinib would be the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million Americans living with MS. Fenebrutinib has shown a manageable safety profile across the three Phase III trials and earlier studies, with a safety database of more than 2,700 study participants.

Genentech, a member of the Roche Group, broke ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon, advancing plans announced in August to increase capacity for advanced drug delivery devices and strengthen United States manufacturing. The expansion adds 211,000 square feet to the site, doubling its size, with commercial operations planned to begin in 2031. Once operational, the facility will add device fill-finish capabilities, including manufacturing of combination products, to Genentech's U.S. manufacturing network, with flexible high- and low-volume filling designed to produce medicines across oncology, neurology and immunology. The expansion will create approximately 250 high-wage manufacturing jobs pairing traditional manufacturing expertise with digital skills in AI, automation and robotics, while construction supports approximately 200 additional construction jobs. The project is part of Roche and Genentech's investment commitment in U.S. manufacturing and R&D and builds on recent manufacturing and investment milestones in Holly Springs, North Carolina and Boston, Massachusetts; Roche and Genentech have approximately 25,000 employees in the U.S., with 15 R&D centers and 13 manufacturing sites.

Roche's experimental obesity drug enicepatide helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial, adding another potentially important asset to the company's effort to challenge obesity-market leaders Eli Lilly and Company and Novo Nordisk A/S. In the 447-patient study, patients receiving the highest 24-milligram dose experienced significant reductions in HbA1c at 48 weeks, meeting the study's two main goals, and Roche said approximately 62% of patients achieved HbA1c levels below 5.7%, putting their blood sugar into the non-diabetic range. The findings follow a separate mid-stage result reported in June in which enicepatide helped overweight or obese patients without diabetes lose 22.7% of their body weight; Roche said the two weight-loss figures should not be directly compared because they come from separate trials involving different patient populations. Roche plans to begin late-stage glycemic-control and cardiovascular-outcomes studies during the first half of 2027, though enicepatide remains an experimental drug and the latest results should not be treated as evidence of regulatory approval or eventual commercial success. Roche said around 2% of patients taking enicepatide in the 447-patient study discontinued treatment because of side effects, compared with none in the placebo group, with most gastrointestinal side effects described as mild to moderate, and the company is betting on next-generation therapies in an obesity market expected to exceed $100 billion in annual sales within the next decade, where AstraZeneca and Amgen are among the large drugmakers also racing to break in.

Roche Holding announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types, and agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide, also known as CT-388, reported positive Phase 2 results in type 2 diabetes and obesity, highlighting Roche's GLP-1/GIP pipeline ambitions. The company's late stage pipeline includes 10 new molecular entities moving into Phase III and the potential launch of up to 19 medicines by the end of the decade, and the full story points toward a CHF370 fair value for Roche Holding. Analysts still flag execution and pricing pressure, especially in China and in obesity where Eli Lilly and Novo Nordisk are strong competitors.

Atavistik Bio has entered a strategic research collaboration with Roche to discover and develop novel allosteric small molecule therapeutics against multiple targets for cardiovascular, renal, and metabolic diseases. Under the agreement, Atavistik Bio will receive a $70 million upfront payment and may be eligible for additional research, development, and commercial milestone payments of up to $1.9 billion, plus tiered royalties on future net sales of any approved medicines resulting from the collaboration. The collaboration will use Atavistik Bio's proprietary AMPS drug discovery platform to identify novel functional binding pockets and advance selective small molecules against CVRM targets. Atavistik Bio will handle discovery and research activities for the collaboration targets, while Roche will lead further preclinical and clinical development, regulatory, and commercialization activities. Bryan Stuart, Chief Executive Officer of Atavistik Bio, said the partnership reflects the strength and broad applicability of the company's allosteric discovery platform, while Boris L. Zaïtra, Head of Corporate Business Development at Roche, said treating CVRM diseases remains a core strategic priority for Roche.

Roche Holding partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The clinical win comes on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date, and a 1-year total shareholder return of 44.02%. Roche Holding now trades at CHF363.20, only about 3% below the average analyst target, yet screens at a roughly 59% discount to an intrinsic value estimate, while the most followed narrative fair value of CHF353.34 pegs the stock as 2.8% overvalued. The SWS DCF model points the opposite way, implying a future cash flow value of CHF893.70. The story could still change quickly if key Phase 3 programs disappoint or if biosimilar pressure on older blockbusters accelerates faster than expected.

Ionis Pharmaceuticals announced positive late-stage results from two partnered phase III programs. The FUSION study of ulefnersen in amyotrophic lateral sclerosis caused by mutations in the fused in sarcoma gene met its primary endpoint assessing functional impairment and survival at 72 weeks, with Ionis reporting the results as statistically significant without disclosing supporting numbers; Otsuka Pharmaceutical, which holds worldwide commercialization rights licensed in 2024, plans to discuss the data with the FDA and other global health authorities regarding potential expedited regulatory submission pathways. Separately, the IMAgINATION study of sefaxersen in adults with primary immunoglobulin A nephropathy, conducted by Ionis' partner Roche, met its primary endpoint in a prespecified interim analysis, showing statistically significant and clinically meaningful reductions in proteinuria after 37 weeks, and will continue in a blinded manner to evaluate kidney function over two years with estimated glomerular filtration rate at week 105 as the longer-term measure. Roche licensed sefaxersen from Ionis in 2022 and is responsible for the phase III study and future global development, regulatory and commercialization activities, while Ionis is eligible for milestone payments and tiered royalties on net sales of both drugs. The two wins follow back-to-back cardiovascular setbacks for Ionis, including the phase III CARDIO-TTRansform failure of Wainua with AstraZeneca in July and the phase III Lp(a)HORIZON miss for pelacarsen with Novartis, and come after the FDA approval of Zanvastro for Alexander disease earlier this month. Year to date, Ionis shares have lost 42% compared with the industry's 2% decline.

Roche announced positive prespecified interim results from the ongoing phase III IMAgINATION study of investigational sefaxersen in adults with primary IgA nephropathy, with the study meeting its primary endpoint of statistically significant and clinically meaningful proteinuria reduction versus placebo at 37 weeks as measured by 24-hour urine protein-to-creatinine ratio. Sefaxersen is a once-monthly subcutaneous injection designed for self-administration that inhibits complement factor B production in the liver, and its safety and tolerability profile was consistent with previously reported data with no new safety signals. The IMAgINATION study enrolled 459 people randomized 1:1 to receive sefaxersen or placebo for 105 weeks and will continue blinded to evaluate change in kidney function over two years as measured by estimated glomerular filtration rate at week 105. Interim data will be presented at an upcoming medical congress and shared with health authorities. Roche licensed sefaxersen from Ionis for the treatment of complement mediated diseases.

Roche announced that the Board of Directors of Roche Holding Ltd has approved proposing Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche's Annual General Meeting on March 9, 2027. Roche Chairman Severin Schwan said he is pleased the company was able to propose Christophe Weber for election, adding that Weber's intimate knowledge of the healthcare industry and his broad leadership experience will further strengthen the Board. Roche, founded in Basel, Switzerland in 1896, is a healthcare company spanning diagnostics, medicines and digital solutions, and is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries. Genentech in the United States is a fully owned subsidiary in the Roche Group, and Roche is the majority shareholder in Chugai Pharmaceutical.

Alibaba shares rose more than 3% after the company unveiled what it called China's most powerful AI chip, claiming three times the performance of its previous generation, and announced plans to expand data center capacity and train a new AI model at the scale of 5 to 10 trillion parameters. On Holding shares climbed 11% as the Swiss sneaker maker said it expects sales growth in the high teens over the next few years while moving into sports including golf and football, though the stock remains down 41% year to date. Viking Therapeutics shares surged about 30% in pre-market trading, having earlier been up more than 50%, after the biotech reported positive top-line results from its VK2735-102 maintenance study showing its experimental obesity drug VK2735 maintained up to 97% of weight loss versus 61% for placebo when subjects switched to every-other-week dosing, with Leerink analysts calling the data stellar and saying it strengthens the drug's competitive profile. The study showed the drug led to 22% weight loss over 33 weeks, positioning it as a potential contender to Eli Lilly and Novo Nordisk. Roche also released positive trial data on its obesity treatment, adding to intensifying competition that left Eli Lilly and Novo Nordisk shares slightly lower.

The European Commission has approved Roche's Susvimo, a ranibizumab 100 mg/mL solution for injection, for the treatment of neovascular age-related macular degeneration, or nAMD, a leading cause of vision loss in people over 60. Susvimo is delivered continuously into the eye through the Contivue refillable implant, making it the first and only continuous delivery treatment offering an alternative to standard-of-care eye injections, and it helps patients maintain their vision with as few as two treatments per year. The approval rests on three clinical studies in nAMD: the pivotal Phase III Archway trial and two supportive studies, the Phase II Ladder study and the open-label long-term extension study Portal, with Archway data showing vision outcomes equivalent to monthly intravitreal ranibizumab injections and Portal data showing vision maintained for up to seven years. With two refills per year, approximately 95% of patients treated with Susvimo required no supplemental anti-VEGF treatment, and the therapy was generally well tolerated over the longer term. Roche was granted a CE mark for its Port Delivery Platform, known as Contivue in the European Union, in 2025; Contivue with Susvimo is also approved for nAMD in Switzerland and Thailand, while in the United States the devices and medicine are approved by the FDA as a single product called Susvimo for nAMD, diabetic macular edema and diabetic retinopathy. nAMD affects approximately 1.7 million people across the European Union and around 20 million people worldwide.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Roche's Ocrevus, or ocrelizumab, intravenous infusion for patients aged 10 years and older with relapsing forms of multiple sclerosis, making it the first high-efficacy anti-CD20 treatment option for people with MS as young as 10 years old. The positive opinion rests on the Phase III OPERETTA 2 study, in which Ocrevus was non-inferior to fingolimod, the current standard treatment in paediatric MS, at controlling relapses and reduced the risk of relapses by 48% compared with fingolimod. In the same trial Ocrevus was superior at reducing brain inflammation, with significant reductions in new or enlarging T2 lesions of 48% and gadolinium-enhancing active T1 lesions of 87%, and its safety profile in children and teens was consistent with that seen in adults, with no patients stopping treatment due to side effects. The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026, and a final decision from the European Commission is expected in the near future. At least 40,000 children and adolescents are living with MS worldwide, with roughly one-third in Europe.

Genentech, a member of the Roche Group, and Roche announced the grand opening of the Roche Genentech Innovation Center Boston, a 95,000 square foot facility at Harvard's Enterprise Research Campus in Allston under a 10-year lease with capacity for up to 500 people. The center focuses on cardiovascular, renal and metabolic diseases, bringing together scientists across discovery research, clinical development, artificial intelligence and data science in an end-to-end research environment spanning early-stage discovery through late-stage clinical development. The Innovation Center is part of Roche and Genentech's $50 billion investment in U.S. manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon. Roche and Genentech have approximately 25,000 employees in the United States, with 15 R&D centers and 13 manufacturing sites. Roche CEO Dr. Thomas Schinecker said the investment in Boston is an important part of the commitment to expand the U.S. manufacturing and R&D footprint, while Genentech CEO Ashley Magargee said the center places scientists at the heart of one of the world's most dynamic research communities.

Roche announced that the phase III CELESTIMO study of Lunsumio, also known as mosunetuzumab, in combination with Revlimid, or lenalidomide, met its primary endpoint in people with relapsed or refractory follicular lymphoma who had received at least one prior line of treatment. The Lunsumio regimen produced a statistically significant and clinically meaningful improvement in progression-free survival versus MabThera/Rituxan, or rituximab, plus Revlimid, while overall survival data were immature at the interim analysis. The safety profile of Lunsumio plus Revlimid was consistent with the known profiles of the individual medicines, with no new safety signals reported. CELESTIMO is the confirmatory study required to convert Lunsumio monotherapy's accelerated approval and conditional marketing authorization for third-line or later follicular lymphoma into full approval, and it is also intended to support an indication in second-line or later disease. Roche plans to submit the data to health authorities and present it at an upcoming medical conference. Separately, Lunsumio is approved as a fixed-duration monotherapy for third-line or later relapsed or refractory follicular lymphoma in both intravenous and subcutaneous formulations, and in June 2026 the FDA accepted Roche's supplemental biologics license application for Lunsumio VELO in combination with Polivy for relapsed or refractory large B-cell lymphoma, with a decision expected on Feb. 9, 2027.

Dualitas Therapeutics announced a research collaboration and license agreement with Roche to discover and develop novel bispecific antibodies for immunology and inflammation diseases using Dualitas' DualScreen Bispecific Discovery Engine. Under the deal, Dualitas will functionally screen more than 300,000 novel bispecific combinations, which the company describes as one of the largest-scale bispecific discovery endeavors, while Roche will handle all subsequent preclinical development, regulatory, manufacturing and commercial activities. Dualitas will receive $36.5 million in upfront payments and is eligible for research, development and commercial milestone payments plus tiered royalties for a potential total deal value of up to $1 billion. Forbes Huang, co-founder, chief operating officer and chief business officer of Dualitas, called the partnership a first-of-its-kind collaboration to functionally screen and develop novel proximity bispecific antibodies at a scale previously unachievable. Boris L. Zaïtra, Head of Corporate Business Development at Roche, said bispecific antibodies remain central to Roche's portfolio strategy across many disease areas, and Karim Dabbagh, chief executive officer and board member of Dualitas, said the collaboration underscores the potential of the company's technologies to identify bispecific antibodies that harness novel proximity mechanisms.

Roche announced that its collaborator MediLink released interim results from the randomized phase III TAISHAN-302 trial showing that Tam-Peli, also known as tambotatug pelitecan or YL201, beat topotecan in Chinese patients with relapsed small-cell lung cancer who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor. The trial met its primary endpoint of overall survival, with Tam-Peli reducing the risk of death by 54 percent, with median overall survival of 13.3 versus 9.4 months and a stratified hazard ratio of 0.46 at a p-value below 0.0001. Tam-Peli also extended median progression-free survival to 7.4 months from 2.8 months and achieved a confirmed objective response rate of 59.1 percent versus 9.7 percent. The results are being presented as a Late-Breaking Abstract during a Presidential Presentation at the IASLC 2026 World Conference on Lung Cancer in Seoul with simultaneous publication in The New England Journal of Medicine, and China's Center of Drug Evaluation has accepted the New Drug Application for filing. Roche, which holds development, manufacturing and commercialization rights for Tam-Peli worldwide outside mainland China, Hong Kong and Macau under a January 2026 exclusive licensing agreement with MediLink Therapeutics, said the data support plans to rapidly initiate global phase III trials.

Roche announced that the FDA has accepted its supplemental biologics license application seeking approval of Enspryng, also known as satralizumab, for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, and granted the application a priority review with a decision expected on Jan. 10, 2027. If approved, Enspryng would become the first and only disease-modifying therapy for MOGAD, a rare autoimmune disease of the central nervous system that can cause unpredictable attacks affecting the optic nerves, spinal cord or brain and for which there are currently no approved treatments. The FDA's acceptance was based on positive data from the phase III METEOROID study, which met its primary endpoint, showing that treatment with Enspryng reduced the risk of a new MOGAD relapse by 68% compared with placebo, and that at 48 weeks 87% of patients treated with Enspryng remained relapse-free compared with 67% in the placebo arm. Separately, the European Medicines Agency has validated Roche's application for Enspryng in MOGAD, with a decision from the European Commission expected in the third quarter of 2027. Enspryng is currently approved in several countries for the treatment of neuromyelitis optica spectrum disorder, including the European Union and the United States, and Roche is also evaluating it in additional neurological autoimmune and inflammatory disorders, with the FDA having accepted and granted priority review in June 2026 to a separate sBLA seeking label expansion for thyroid eye disease and a final decision expected on Oct. 15, 2026.

DelveInsight projects the ulcerative colitis market across the seven major markets—the US, EU4, UK, and Japan—will grow from approximately USD 9.4 billion in 2025 at a CAGR of 7.6% through 2036, driven by novel targeted therapies and a robust pipeline of late-stage candidates. Among these, Abivax's obefazimod, a first-in-class oral miR-124 enhancer, met its primary endpoint in Phase III ABTECT induction studies, with a pooled placebo-adjusted clinical remission rate of 16.4% at Week 8. Merck's tulisokibart, acquired via Prometheus Biosciences, achieved clinical remission in the Phase 3 ATLAS-UC study, while Roche's afimkibart, from its $7.1 billion Telavant acquisition, showed a 35% remission rate in Phase IIb TUSCANY-2. Johnson & Johnson and Protagonist Therapeutics' icotrokinra, a first-in-class oral IL-23 receptor antagonist, met its primary endpoint in the Phase 2b ANTHEM-UC trial, and Teva and Sanofi's duvakitug, backed by a $400 million Blackstone funding deal, is in Phase III. These therapies target unmet needs in moderate-to-severe disease, with the market shifting toward IL-23 inhibitors and oral advanced therapies, though biosimilars and established anti-TNFs remain widely used.

Roche Holding announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas, and received FDA clearance for its Elecsys pTau217 blood test, the first single biomarker assay to help rule in and rule out amyloid pathology in Alzheimer's disease. The test is intended to support earlier and more accessible Alzheimer's diagnostic assessments. Roche, a pharmaceuticals and diagnostics group with a CHF285.2 billion market cap, is expanding its oncology pipeline through partnerships and its diagnostics portfolio with neurology assays. The lymphoma partnership and the blood test clearance align with Roche's strategy of combining pipeline breadth and diagnostics depth, though the company faces competition from Novartis, Bristol Myers Squibb, Abbott, and Siemens Healthineers.

Treeline Biosciences has announced a clinical trial collaboration and supply agreement with Roche to evaluate its BCL6 degrader TLN-121 in combination with Roche's CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab for B-cell lymphomas. Under the agreement, Treeline will sponsor and conduct a Phase 1 dose escalation and expansion study, with Roche supplying the antibodies for specific expansion cohorts, and combination dosing is expected to begin in the fourth quarter of 2026. Preclinical data presented by Treeline show that TLN-121 enhances anti-tumor activity when combined with these bispecific antibodies or with CD19 CAR-T cell therapy, including complete regressions in mouse models of diffuse large B-cell lymphoma. Treeline's CEO Josh Bilenker expressed excitement about building on the progress of these bispecific antibodies in collaboration with Roche.

Roche has committed $75 million upfront for global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660, in a deal that could be worth up to $1.53 billion. The Swiss pharmaceuticals and diagnostics giant will gain exclusive development, manufacturing, and commercialization rights outside Simcere's retained markets, with up to $1.455 billion in potential milestone payments and tiered royalties reaching double-digit percentages. The drug remains preclinical, and Roche's upfront payment represents just 4.9% of the deal's maximum value, keeping the early financial risk low. Roche's U.S.-quoted shares fell to $53.55 on Tuesday, trading 30.01% above the GF Value of $41.19, indicating a premium valuation while the drug is far from commercialization.

Roche's Columvi (glofitamab) will be added to Singapore's Cancer Drug List and Medication Assistance Fund on 1 September 2026, providing subsidised access for eligible patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant and have received at least one prior therapy. Under the Medication Assistance Fund, eligible Singapore Citizens and Permanent Residents will receive subsidies of up to 75% and 20% respectively at public healthcare institutions. The treatment, used in combination with gemcitabine and oxaliplatin, offers a new off-the-shelf option alongside existing therapies such as CAR-T cell therapy and chemotherapy. In the pivotal phase III STARGLO study, overall survival was twice as long for patients treated with Columvi plus GemOx versus rituximab plus GemOx, at 25.5 months versus 12.9 months, with 38% of patients remaining in remission at 30 months compared to 15% in the comparator arm. Lymphoma is the fourth most common cancer among men and fifth among women in Singapore, with DLBCL accounting for roughly 30% of local lymphoma diagnoses.

Alnylam Pharmaceuticals presented new data at the European Society of Cardiology Congress 2026, reinforcing the strength of RNAi-powered TTR silencing across ATTR-CM patient populations and treatment settings. A late-breaking prespecified subgroup analysis of the HELIOS-B Phase 3 trial showed that vutrisiran provided consistent clinical benefit on all-cause mortality and recurrent cardiovascular events in patients with or without tafamidis use at baseline, among 654 randomized patients, 40% of whom were on tafamidis. Additional post hoc analyses highlighted vutrisiran's positive impact on multisystemic manifestations, including a 25% less decline in intrinsic capacity and a 52% reduction in risk of decline. A pooled analysis of 1,402 patients across four Phase 3 studies of vutrisiran and patisiran showed consistent treatment effects across sexes. New subgroup data from the KARDIA-3 Phase 2 study of zilebesiran suggested potential for enhanced blood pressure control, particularly in patients on background diuretics with elevated systolic BP. These findings support the ongoing Phase 3 ZENITH trial for zilebesiran, co-developed with Roche.

Roche Holding has received FDA approval for its Elecsys pTau217 blood test for Alzheimer's disease in the U.S., a diagnostic designed to identify amyloid pathology from a blood sample and widen access to dementia testing across American labs. The FDA also cleared expanded use of Roche's PATHWAY HER2 and VENTANA HER2 Dual ISH tests in metastatic gastroesophageal cancers, broadening options for HER2 testing in cancer care. These approvals highlight how diagnostics and healthcare AI are reshaping clinical workflows, and they fit into Roche's broader strategy of expanding its companion diagnostics portfolio. Investors should watch how quickly U.S. labs adopt the Elecsys pTau217 test across the 4,500 installed cobas instruments, as well as reported testing volumes for the HER2 assays, to gauge the impact on Roche's diagnostics growth.

A Delaware federal jury has ordered Qiagen subsidiary Parse Biosciences to pay more than $4.8 million in damages for infringing three patents licensed by 10x Genomics' Scale Biosciences unit from Roche. The jury also rejected Parse's claims that the patents were invalid, affirming they are valid and enforceable. The damages are based on a 14% royalty rate on sales of infringing products from February 2021 through June 30, 2026. 10x Genomics said it will seek a permanent injunction and additional awards for attorneys' fees and enhanced damages in post-trial proceedings.

The global cytotoxic drugs market is projected to grow from $16.21 billion in 2026 to $21.06 billion by 2031, at a compound annual growth rate of 5.37%, according to a new report from ResearchAndMarkets.com. Rising cancer incidence, earlier diagnosis, expanded reimbursement, and growing demand in emerging economies are driving the market. In 2025, the market was valued at $15.38 billion, with parenteral drugs holding a 68.87% share, while oral drugs are expected to grow faster at an 8.79% CAGR. Alkylating agents led with a 30.10% share in 2025, but antimetabolites are forecast to grow fastest at 7.02% CAGR. North America accounted for 42.15% of revenue in 2025, while Asia-Pacific is projected to grow at 10.07% CAGR, supported by China's approval of 228 drugs in 2024, 37% of which were antineoplastics. Key players include Pfizer, Roche, Novartis, AstraZeneca, and Sanofi.

Roche announced new two-year data from the Phase IIIb/IV SALWEEN study showing that Vabysmo (faricimab) significantly improved vision and retinal health in patients with polypoidal choroidal vasculopathy (PCV), a severe subtype of neovascular age-related macular degeneration (nAMD). The study, presented at the 19th Asia-Pacific Vitreo-retina Society Congress, found that patients gained 7.3 letters in best-corrected visual acuity and had a reduction of 127 micrometers in central subfield thickness from baseline averaged over weeks 100 to 108. At year two, 74% of patients had no retinal fluid, and complete regression of polypoidal lesions occurred in 62% of eyes, with inactivation in 86%. More than 60% of patients were on an extended 20-week treatment interval by the end of year two, reducing treatment burden. Vabysmo was well tolerated with a safety profile consistent with its known profile in nAMD. The study enrolled 135 patients from nine Asian markets, including China, Japan, and South Korea.

The U.S. Food and Drug Administration has granted clearance to the Elecsys pTau217 blood test, developed by Eli Lilly and Roche, making it the first and only FDA-cleared single-biomarker blood test for Alzheimer's that can both rule in and rule out amyloid-beta pathology using one validated clinical cutoff. With an estimated 7.4 million Americans aged 65 and older currently living with clinical Alzheimer's dementia, a figure projected to nearly double to 13.8 million by 2060, and national care costs expected to reach $409 billion this year, the approval is set to expand the eligible patient pool for disease-modifying therapies, potentially boosting the global Alzheimer's DMT market to $13.1 billion by 2030. Healthcare ETFs such as the State Street Health Care Select Sector SPDR ETF, iShares Global Healthcare ETF, VanEck Pharmaceutical ETF, and iShares Neuroscience and Healthcare ETF offer diversified exposure to these pharmaceutical giants and the growing Alzheimer's treatment market.